Supportive Oligonucleotide Therapy (SOT) for Lyme Disease
In their article
“Supportive Oligonucleotide Therapy (SOT) as a Potential Treatment for Viral Infections and Lyme Disease: Preliminary Results,”
Apostolou and colleagues describe findings from a study evaluating the potential role of Supportive Oligonucleotide Therapy (SOT) in patients with viral infections and Lyme disease.1
The study included 115 patients with either Epstein–Barr virus (EBV), Herpes Simplex Virus (HSV), or Lyme disease.
How SOT works
Oligonucleotide therapy was administered intravenously to participants. Polymerase chain reaction (PCR) testing was then performed to evaluate the effect of SOT on microbial DNA levels.
Treatments were designed to inhibit proteins that are essential for microbial survival.
DNA was isolated from both cells and serum of individuals with Lyme disease. The authors targeted outer surface proteins (OspA and OspB) found on Borrelia burgdorferi spirochetes.
“SOT might be beneficial for patients with Lyme disease or infections by viruses, such as EBV and HSV.”
According to the authors, “This study revealed that for Lyme disease, one or two SOT administrations can lead to a statistically significant decrease in DNA copies.”
Unanswered questions about SOT therapy
Research Genetic Cancer Center (RGCC) laboratories in Greece have produced SOT for the treatment of Lyme disease.
Apostolou and colleagues reported reductions in the number of detected DNA copies. However, their study was not designed to determine whether lowering DNA copies improves patient symptoms or outcomes.
The study also did not evaluate the long-term safety or overall clinical effectiveness of SOT for Lyme disease patients.
In addition, the authors did not address how this therapy might perform when other factors are present, including:
- Co-infections such as Bartonella or Babesia
- Persistent forms of Borrelia
- Biofilms that may protect bacteria from treatment
Further research is needed to determine whether SOT therapy can safely and effectively improve outcomes for patients with Lyme disease.
Related Articles:
New treatments for Lyme disease on the horizon?
References:
- Apostolou P, Iliopoulos A, Beis G, Papasotiriou I. Supportive Oligonucleotide Therapy (SOT) as a Potential Treatment for Viral Infections and Lyme Disease: Preliminary Results. Infect Dis Rep. 2022;14(6):824-836. doi:10.3390/idr14060084
Has methylene blue been used for treatment of the various tickborne diseases? In reading about this material and its ability to stimulate mitochondrial electron transfer during terminal oxidase function leading to production of ATP, it is found that MB also has characteristics well worth looking at, perhaps as a co-reactant with other medicinals such as atovaquone, zithromax, proguanil, and others. MB is not well researched but there have been preliminary tests showing it is a legit candidate for trial.
I don’t know methylene blue well enough to comments. Sorry
my daughter is on this from our doctor – he really likes it
Does anyone do Sot therapy for bartonella henselae and ebv in NY?Is so do you know how many treatments and total cost?
I just scheduled mine near Albany. The SOT itself was $2500 but it was also $500 for the initial visit, and Ozone dialysis was recommended beforehand so the SOT would have a better chance of efficacy. That was about $2500 additional.